Loading the comparison…
Loading the comparison…
Metabolic & Weight
The dual GIP/GLP-1 agonist behind Mounjaro and Zepbound.
Metabolic & Weight
A long-acting amylin analog — the 'Cagri' half of CagriSema.
Tirzepatide is FDA-approved and rated 5/5 for evidence; Cagrilintide is not FDA-approved and rated 4/5. Tirzepatide has more human evidence behind it. Cagrilintide is banned in sport by WADA; Tirzepatide is not. Both are used for metabolic & weight goals.
| Compare | Tirzepatide The dual GIP/GLP-1 agonist behind Mounjaro and Zepbound. | Cagrilintide A long-acting amylin analog — the 'Cagri' half of CagriSema. |
|---|---|---|
| Category | Metabolic & Weight | Metabolic & Weight |
| Evidence | 5/5FDA-approved on the basis of large phase 3 programs (SURPASS for diabetes, SURMOUNT for obesity, SURMOUNT-OSA for sleep apnea). | 4/5Phase 2 RCT of cagrilintide alone and large phase 3 RCTs (REDEFINE) with a cagrilintide-only arm. Not approved as a standalone drug. |
| FDA status | FDA-approved (Mounjaro 2022, Zepbound 2023) | Not FDA-approved |
| WADA (sport) | Not on the Prohibited List | Banned |
| Also known as | Mounjaro, Zepbound, LY3298176, AMP-2 (TR) | NN9838, AM833, Cagri |
| How it works | A 39-amino-acid peptide with a C20 fatty diacid at lysine-20 that binds albumin, so it lasts about 5 days. GLP-1 and GIP receptor activation lowers appetite, slows stomach emptying, and boosts insulin release when blood sugar is high. | A 37-amino-acid modified amylin analog with a C18 fatty diacid for a long half-life. It activates amylin and calcitonin receptors in the brain, increasing fullness and slowing stomach emptying — a different pathway from GLP-1, which is why the two are combined. |
| Half-life | About 5 days (once-weekly dosing) | About 7–8 days (once-weekly dosing) |
| Commonly reported doses |
|
|
| Route | Subcutaneous (abdomen, thigh, upper arm) | Subcutaneous |
| Good once mixed | ~28 days in the fridge | ~28 days in the fridge |
| Top side effects |
|
|
| Lowest research-listing price per mg | $1.10 (60 mg vial, 40% off) | $4.20 (10 mg vial, 40% off) |
| Latest lab purity | 99.90% (lot TRZ0003) | 99.84% (lot CAG0002) |
Want a third? Add another peptide. Doses are commonly reported ranges, not recommendations.
Free for ChatGPT and Claude
Connect MyPeps to ChatGPT or Claude and ask follow-ups about Tirzepatide and Cagrilintide. It answers from these same pages, with links back here.
Tirzepatide is FDA-approved and rated 5/5 for evidence; Cagrilintide is not FDA-approved and rated 4/5. Tirzepatide has more human evidence behind it. Cagrilintide is banned in sport by WADA; Tirzepatide is not. Both are used for metabolic & weight goals.
Tirzepatide: FDA-approved (Mounjaro 2022, Zepbound 2023). Cagrilintide: Not FDA-approved. Regulations change, so confirm with the FDA.
Tirzepatide is rated 5 out of 5: FDA-approved on the basis of large phase 3 programs (SURPASS for diabetes, SURMOUNT for obesity, SURMOUNT-OSA for sleep apnea). Cagrilintide is rated 4 out of 5: Phase 2 RCT of cagrilintide alone and large phase 3 RCTs (REDEFINE) with a cagrilintide-only arm. Not approved as a standalone drug. The scale is explained on our methodology page.
Tirzepatide is not named on the WADA list, though the general rule on non-approved substances (S0) can still apply. Cagrilintide is banned by WADA, by name or as part of a named class.